by admin | Jan 22, 2018 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
America is facing one of the worst influenza seasons in recent history. The influenza virus is one of the top ten causes of death in elderly people. Longeveron is conducting a multi-center, randomized, placebo controlled trial using its Longeveron Mesenchymal Stem...
by admin | Jan 22, 2018 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients with Alzheimer’s Disease. Longeveron’s Phase I, prospective, randomized, placebo-controlled, double-blinded study is designed to test the safety and efficacy of Longeveron Mesenchymal Stem...
by admin | Jan 22, 2018 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
Longeveron is currently enrolling subjects in its Phase 2b multi-center clinical trial designed to test the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) for the treatment of subjects with clinically diagnosed with Aging Frailty. This is the only...
by admin | Jan 21, 2018 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
PRESS RELEASE Marketwired Jan. 21, 2018, 08:20 AM FREEHOLD, NJ (Marketwired – January 21, 2018) – Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that President and Chief Executive Officer David...
by admin | Jan 18, 2018 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
January 17, 2018 By Cade Hildreth (CEO) Leave a Comment I am honored to share this interview with Bernard Siegel, Executive Director of the Regenerative Medicine Foundation (RMF), a global network of stakeholders that fosters collaboration across the industry. Bernard...
